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Small interfering RNA (siRNA) is an effective and specific method for silencing genes. 
However, an efficient and non-toxic carrier is needed to deliver the siRNA into the tar-
get cells. Tumor necrosis factor α (TNF-α) plays a central role in the occurrence and 
progression of rheumatoid arthritis (RA). In this study, we pre-synthetized a degradable 
cationic polymer (PDAPEI) from 2,6-pyridinedicarboxaldehyde and low-molecular-weight 
polyethyleneimine (PEI, Mw = 1.8 kDa) as a gene vector for the delivery of TNF-α shRNA. 
The PDAPEI/pDNA complex showed a suitable particle size and stable zeta potential for 
transfection. In vitro study of the PDAPEI/pDNA complex revealed a lower cytotoxicity 
and higher transfection efficiency when transfecting TNF-α shRNA to macrophages 
by significantly down-regulating the expression of TNF-α. Moreover, the complex was 
extremely efficient in decreasing the severity of arthritis in mice with collagen-induced 
arthritis. PDAPEI delivered TNF-α shRNA has great potential in the treatment of RA.
Keywords: rheumatoid arthritis, rna interference, TnF-α, PDaPei
inTrODUcTiOn
Rheumatoid arthritis (RA) is a chronic systemic autoimmune disorder with complex causes, which 
leads to cartilage loss and synovial inflammation (1, 2). Many different immune cells and the cytokines 
they produce contribute as mediators to RA pathogenesis in cartilage and bone tissue (3, 4). Among 
the cytokines produced, TNF-α is the key mediator of inflammation in RA, and macrophages are 
highly activated cells in the inflamed synovial membranes of RA (5, 6). Antagonists of biotherapies 
can neutralize TNF-α at the protein level and decrease joint inflammation, but to date, no long-term 
studies have been fully conducted (7, 8).
Anti-TNF-α antibodies has shown its efficacy in RA and is widely used clinically (9, 10). However, 
lower mRNA concentration regulated by gene transcription shows a more efficient and long-lasting 
way (11). Small interfering RNA (siRNA) silencing blocks the expression of specific genes and has 
great potential for treating a wide range of illnesses (12–14). Much work has already been done on the 
silencing of TNF-α and on the downregulation of both local and systemic inflammation in the treat-
ment of RA (15–17). However, siRNA-based therapies for RA have yet to overcome the obstacles of 
designing vehicles capable of both protecting and delivering siRNAs (18). Viral and non-viral vectors 
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have been widely used for gene delivery and delivering an adequate 
amount of siRNA to target cells (19, 20). Cationic polymers have 
the advantage of better biocompatibility, lower immunogenicity, 
and easier modification, which can form polyplexed structures 
with negatively charged siRNA (21, 22). Polyethylenimine (PEI) 
has also been widely used in gene delivery, but its cytotoxic-
ity limits its further application (23). Low-molecular-weight 
PEI (<20  KDa) cross-linked by degradable linkers, however, 
shows a lower cytotoxicity and higher transfection efficiency 
(24, 25). In the present study, PEI 1.8 kDa was cross-linked by 
2,6-pyridinedicarboxaldehyde (PDA) to develop a biodegradable 
low-molecular-weight cationic polymers (PDAPEI). In an acidic 
environment, the PDAPEI shows self-degradation into non-toxic 
low-molecular-weight PEI and 2,6-PDA (26).
Herein, we investigated TNF-α shRNA delivered by PDAPEI 
for the treatment of RA. We examined its characteristics, 
cytotoxicity, transfection efficiency, and gene expression on 
macrophages. PDAPEI/pDNA was also used to treat mice with 
collagen-induced arthritis (CIA), and the therapeutic efficacy was 
evaluated using histological examination.
MaTerials anD MeThODs
Materials
Polyethylenimine 1.8 kDa and 25 kDa and anhydrous ethylene 
dichloride were purchased from Sigma-Aldrich. 2,6-PDA was 
purchased from TCI (Shanghai) Development Co., Ltd. Cellulose 
membranes (MWCO 10,000 Da) were purchased from Thermo 
Scientific. Poly (ethylene glycol) (PEG) standards kit (ranging 
from 106 to 20,100 Da in molecular weight) was purchased from 
Polymer Standards Service GmbH. Water was purified using a 
milli-Q instrument (Millipore). All the reagents were used with-
out further purification. For TNF-α gene silencing, Plasmid DNA 
encoding green fluorescence protein (GFP) and mouse TNF-α 
shRNA were constructed by Bioroot Biology (Shanghai, China) 
according to a previous report that used the following sequence: 
5′-GACAACCAACUAGUGGUGCdTdT-3′. The RAW 264.7 
macrophage cell line was purchased from the cell bank of the 
Chinese Academy of Sciences (Shanghai, China).
synthesis of Polymers
First, 1  mmol PEI 1.8  kDa and 20  ml anhydrous ethylene 
dichloride solution were mixed until completely dissolved. Then, 
2 mmol PDA in 20 ml anhydrous ethylene dichloride solution 
was added and stirred for 48  h at room temperature. After 
removing the solvent by evaporation, the residue was dissolved 
in deionized water and dialyzed through the cellulose membrane 
(<10  k). Then, following lyophilization, we were left with the 
yellow polymers, referred to as PDAPEI.
Preparation and characterization 
of PDaPei/pDna complex
PDAPEI/pDNA complexes were prepared at different weight/
weight (w/w) ratios of 1–50. First, PDAPEI was dissolved with 
deionized water (2  mg/ml) and pDNA (2  mg/ml). Then, the 
PDAPEI solution was diluted to different concentrations and 
added rapidly into the pDNA solution. Next, the solutions were 
incubated at room temperature for 30  min, and PEI/pDNA 
complexes and naked pDNA were simultaneously prepared as 
controls.
Agarose gel electrophoresis assay was used to evaluate the 
condensation ability of PDAPEI/pDNA complexes at different 
w/w. The particle size and zeta potential of PDAPEI/pDNA com-
plexes were measured using a particle size analyzer (Brookhaven 
Instruments) and a zeta potential analyzer (Zetasizer Nano, 
Malvern Instruments) at different w/w ratios. Zeta potential 
across a range of pH (5.4, 6.4, 7.4, 8.4, 9.4) was measured to 
analysis its stability and degradation. The morphology of the 
PDAPEI/pDNA complexes was observed by Transmission elec-
tron microscopy (JEOL JEM 2010 system).
In Vitro study
Macrophage Culture
The RAW 264.7 macrophage cell line was cultured in Roswell 
Park Memorial Institute-1640 (RPMI-1640) containing 10% fetal 
bovine serum, 100 IU/ml penicillin, and 10 μg/ml streptomycin 
at 37°C inside a 5% CO2 atmosphere.
Cytotoxicity of the PDAPEI/pDNA Complex
For the cytotoxicity of the PDAPEI/pDNA complex in RAW 
264.7, cells (1.0 × 104/well) were seeded into 96-well plates and 
incubated for 24 h. Then, a 10-μl PDAPEI/pDNA solution (w/w 
from 1 to 50) was added into each well for an additional 4-h 
incubation. A cell counting Kit-8 (CCK-8) reagent was used to 
evaluate the cytotoxicity of the complexes. Briefly, 10 μl of the 
CCK8 reagent was added into each well and cultured for another 
2 h and measured at 450 and 630 nm using multifunctional micro-
plate reader (SpectraMax M3 Multi-Mode Microplate Reader). 
Similarly, PEI/pDNA complexes and PEI 1.8  kDa/pDNA were 
examined as controls.
Transfection Efficiency
The constructed shTNF-α was encoded with a GFP for deter-
mining the transfection efficiency. RAW 264.7 (5–10 × 104/ml) 
were seeded into 12-well plates and cultured for 24  h. Next, 
the medium was replaced by solutions containing 200  μl of 
PDAPEI/pDNA complexes of different w/w ratios and 800 μl 
RPMI-1640 for an additional 4  h of incubation. Then, the 
transfection medium was removed, and 1  ml of RPMI-1640 
(10% FBS and 1% antibiotics) was added for 48-h incubation. 
We also prepared PEI 1.8  kDa/pDNA as the negative control 
and PEI 25 kDa/pDNA (w/w ratio of 2) as the positive control. 
A fluorescent microscope (Olympus, Tokyo, Japan) and flow 
cytometer (BectoneDickinson, Franklin Lakes, NJ, USA) were 
used to quantify the GFP-positive cells.
TNF-α Silencing Experiment
To evaluate the gene silencing efficiency of PDAPEI/pDNA 
in  vitro, RAW 264.7 cells were seeded in 12-well plates and 
cultured for 24  h. The cells were treated with PDAPEI/pDNA 
complexes (w/w ratio of 20) for 4  h, PEI 1.8  kDa/pDNA and 
PBS was used as a negative control and PEI 25 kDa/pDNA (w/w 
ratio of 2) was used as a positive control. Then, the transfection 
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medium was replaced with fresh RPMI-1640 (10% FBS and 1% 
antibiotics) and incubated for 24/48 h. ELISA measurement was 
applied to detect TNF-α expression in the supernatant according 
to the manufacturer’s instructions (R&D Systems, Minneapolis, 
MN, USA). Total RNA was extracted from the cells using 
RNeasy®Mini Kit (Qiagen, Valencia, CA, USA) and reverse 
transcribed into cDNA using High-Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems). The cDNAs for TNF-α 
were amplified by RT-PCR under the following conditions: 
denaturation at 95°C for 10 s; 40 cycles of amplification at 95°C 
for 15 s, and 60°C for 30 s. The specific primers used to detect 
mouse TNF-α (forward: 5′-AGTGGAGGAGCAGCTGGAGT-3′; 
reverse5′-TCCCAGCATCTTGTGTT TCTG-3′) were synthe-
sized and purified by TAKARA, Inc. Then, the qPCR products 
were subjected to electrophoresis on 2% agarose gels and visual-
ized with UV light.
animal study
Animal Model and Treatment
Healthy male DBA/1 mice were purchased from the Institute of 
Zoology, Chinese Academy of Sciences (Beijing, China). All ani-
mals survived under specific pathogen-free (SPF) environment 
in a laboratory within the animal facility located at the school of 
pharmacy, Shanghai Jiao Tong University. All mice were housed 
under standardized laboratory conditions and monitored to 
observe changes in ordinary conditions and activities. Animal 
care and use were in accordance with the guidelines established 
by the Administration of Affair Concerning Laboratory Animals 
for Shanghai JiaoTong University, the National Institutes 
of Health Guide for care and Use of Laboratory Animals 
(GB14925-2010) and the Regulations for the Administration 
of Affairs Concerning Experimental Animals (China, 2014). 
The murine CIA model was prepared according to a previous 
study (27). Type II collagen was used as an autoantigen for 
first immunization and booster immunization (3  weeks after 
first immunization until the model was successfully made, mice 
without symptoms were eliminated). Twenty-four CIA mice 
were randomly divided into four groups (six mice per group): 
saline, PEI 1.8 kDa/DNA complex, PEI 25 kDa/pDNA complex 
and PDAPEI/pDNA complex, after receiving their booster 
immunization. Each group received intravenous injections of 
saline, pDNA (1.5 mg/kg shRNA), PEI 25 kDa/pDNA complex 
(at w/w ratio of 2, 1.5  mg/kg shRNA) and PDAPEI/pDNA 
complex (at proper w/w ratio, 1.5 mg/kg shRNA) according to 
the in  vitro study results 1  week after booster immunization. 
The treat injection was repeated once a week until 5 weeks when 
the therapeutic efficacy was analyzed.
Clinical Examination
Arthritic severity was recorded based upon the clinical scores of all 
four paws. Clinical severity of arthritis for each paw was classified 
as follows: 0 (normal joints), 1 (slight redness and/or swelling), 
2 (pronounced edematous swelling), and 3 (joint deformity and 
rigidity). The total clinical score was calculated by averaging all 
four paws scores. Hind paw edema was also measured by digital 
Vernier caliper to determine the severity.
Measurement of TNF-α in Knee
Before the mice were sacrificed for histological examination, 
synovial fluid was collected from the knees to measure TNF-α by 
ELISA and western blot, as per the instructions of the manufac-
turer and our previous study.
Histological Examination
At 6  weeks after the first immunization, the knee joint tissues 
of each group were collected and fixed in fixative/decalcifier for 
safranin O/fast green staining. Anti-TNF-α immunohistochemi-
cal analysis was applied to each knee joint. Briefly, 5-μm-thick 
sections of frozen tissue blocks were stained with mouse mono-
clonal anti-TNF-α antibody (1:1,000) and peroxidase-conjugated 
goat anti-mouse immunoglobulin G (H + L) secondary antibody 
(1:5,000) for further detection.
statistical analysis
The statistical analyses were performed as the mean ±  SD by 
one-way ANOVA with a value of *P <  0.05 being considered 
statistically significant.
resUlTs
Preparation of PDaPei
Proton nuclear magnetic resonance (1H NMR) and Fourier 
transform infrared spectroscopy (FT-IR) were used to confirm 
the structure of PDAPEI. The chemical shifts of 1H NMR and 
transmittance attribution in FT-IR were in agreement and as 
had been desired. The average molecular weight of PDAPEI 
was 21,000 Da, as measured by gel permeation chromatography 
(Figures 1A,B).
Preparation and characterization  
of the PDaPei/pDna complex
The complex was successfully made per the above instructions. 
As shown in Figure 2, in the agarose gel electrophoresis assay, 
particle size and Zeta potential measurement and morphol-
ogy analysis confirmed the formation and characterization of 
PDAPEI/pDNA complex. The gel electrophoresis indicated 
that PDAPEI condensed pDNA completely at a w/w ratio of 1 
(Figure  2A). The particle size of PDAPEI/pDNA was stable at 
80 nm, with a variety in w/w from 1 to 50, showed almost no 
difference compared with PEI 25  kDa/pDNA (Figure  2B left). 
PDAPEI/pDNA complex and PEI 25 kDa/pDNA (PH = 7.4) kept 
constant positive charges of ~22  mV with increased w/w ratio 
(from 10 to 40) (Figure 2B right). The Zeta potential of PDAPEI/
pDNA complex (at w/w ratio of 20) was around 57 mV in acidic 
environment (pH = 5.4) and −9 mV in alkalinity environment 
(pH = 9.4), which decreased with increasing pH. The morpho-
logical analysis under TEM shoed the particle had a uniform 
diameter and spherical shape, consistent with the particle size 
measurement (Figure 2C).
In Vitro Cytotoxicity and Transfection Efficiency
The cytotoxicity of PDAPEI to RAW246.7 was determined by 
the CCK-8 assay and the results were shown in Figure  3A. 
FigUre 1 | The PDaPei structure was confirmed using 1h nMr and FT-ir. (a) NMR of PDAPEI. Chemical shifts at δ7.7 ppm of the 1H NMR spectrum are 
attributed to the protons of 2,6-pyridinedicarboxaldehyde. (B) IR of PDAPEI. This attribution is in agreement with the stretching vibration of the carbonyl group at 
1,651 cm−1 in the FT-IR spectrum for 2,6-Pyridinedicarboxaldehyde carbonyls.
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FigUre 2 | characteristics of PDaPei/pDna complexes. (a) Gel electrophoresis indicated that PDAPEI condensed TNF-α shRNA completely at the w/w ratio 
of 1 or above (w/w = PDAPEI/TNF-α shRNA). (B) Particle size and zeta potential of polymer/DNA complexes (different w/w). (c) Morphology of PDAPEI/pDNA is 
observed by transmission electron microscopy (TCM).
5
Song et al. TNF-α Silencing for Rheumatoid Arthritis
Frontiers in Immunology | www.frontiersin.org August 2016 | Volume 7 | Article 305
FigUre 4 | expression of TnF-α in vitro. (a) TNF-α expression of 
RAW246.7 cells determined by ELISA measurement 24/48 h after 
transfected with TNF-α shRNA by different polymers. (B) Relative levels of 
TNF-α mRNA expression was corrected by GAPDH. Data represent fold 
change of relative TNF-α expression normalized to GAPDH levels. (*p < 0.05, 
**p < 0.01).
FigUre 3 | cytotoxicity and transfection efficiency in vitro.  
(a) Cytotoxicity of PDAPEI to RAW246.7 cells tested by CCK-8 assay (viability 
cells %) at different w/w. (B) Transfection efficiency of PDAPEI to RAW246.7 
cells measured with flow cytometry (EGFP positive cells %) at different w/w 
(red: PDAPEI/pDNA, yellow: PEI 25 kDa/pDNA, black: PEI 1.8 kDa/pDNA). 
The experiments have been repeated for three times. (*p < 0.05, **p < 0.01).
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Compared with PEI25 kDa/pDNA control group, PDAPEI/
pDNA showed significantly lower cytotoxicity at different w/w 
ratios. With the w/w ratios increasing from 1 to 50, PDAPEI/
pDNA complex was kept at a low cytotoxicity, with cell viability 
higher than 90%, there was no difference with the PEI 1.8 kDa/
pDNA control group.
The GFP-positive RAW246.7 was observed with a fluores-
cence microscope. Almost no fluorescence was observed in the 
PEI 1.8  kDa/pDNA group and PBS control group, while obvi-
ous fluorescence was observed in the PDAPEI/pDNA and PEI 
25 kDa/pDNA group. The flow cytometry results demonstrated 
that the PDAPEI/pDNA group showed a significantly higher 
GFP-protein level than PEI 1.8  kDa/pDNA at all w/w ratios. 
With the w/w ratio increasing from 1 to 50, the percentage of 
GFP-positive cells increased from 8 to 25%. Compared with PEI 
25  kDa/pDNA (w/w ratio of 2), the PDAPEI/pDNA showed a 
similar percentage of GFP-positive cells (w/w ratio from 1 to 10) 
and a significantly higher percentage of GFP-positive cells (w/w 
ratio of 20–50) (Figure 3B).
Expression of TNF-α In Vitro
The expression of TNF-α in  vitro was measured by ELISA. As 
shown in Figure 4A, TNF-α in the supernatant was significantly 
reduced in the PDAPEI/pDNA group compared with other three 
groups after 24-h transfection. The concentrations of TNF-α 
were 22 ± 5.4 and 20.1 ± 6.5 ng/ml in the PBS control group and 
PEI 1.8 kDa/pDNA group, respectively, significantly higher than 
that of the PEI 25 kDa/pDNA group (14.2 ± 2.4 ng/ml, p < 0.05) 
and PDAPEI/pDNA group (6.1 ± 1.2 ng/ml, p < 0.01) 48 h after 
transfection. To further determine the in vivo silencing effect of 
TNF-α shRNA transfected by PDAPEI, real-time RT-PCR was 
utilized to measure the TNF-α microRNA expression. The mean 
levels of TNF-α microRNA expression in the PDAPEI/pDNA 
group were 23% of those in the PBS control group 48  h after 
transfection (Figure 4B).
Animal Model and Clinical Examination
The mouse CIA model was used to determine the effects of 
PDAPEI/pDNA on RA. To get 24 CIA mice, there were 21 mice 
without symptoms after booster immunization and these mice 
were eliminated from further study. The w/w ratio of PDAPEI/
pDNA chosen was 20 according to previous in  vitro results. 
No severe complications were observed throughout the experi-
ment. As shown in Figure 5, mice treated with PDAPEI/pDNA 
exhibited significant reductions in the severity of CIA. During 
weeks 1–5 after booster immunization, the arthritis severity score 
decreased from 1.5 ± 0.2 to 0.2 ± 0.1, showing a significant dif-
ference when compared with saline group. The arthritis score for 
the saline control group was 2.5 ± 0.5 during the first week after 
booster immunization and maintained that score level through-
out the experiment. The PEI 1.8 kDa/pDNA and PEI 25 kDA/
pDNA groups lower scores than saline, but were not of significant 
difference (Figure 5A). We also examined edema by measuring 
FigUre 5 | clinical scores of arthritis symptoms. (a) Clinical arthritis score. (B) Paw swelling. Data were monitored every week after booster immunization, 
presented as mean ± SEM (n = 6 in each group, *p < 0.05, **p < 0.01).
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the thickness of hind paw and found the results corresponded 
with the arthritic scores (Figure 5B).
TnF-α expression in synovial Fluid  
of the Knees
Enough synovial fluid obtained from the knee in each group 
(0.1 ml at least) was used for ELISA and western-blot analysis. 
The level of TNF-α expression in synovial fluid of the knees was 
212.45 ± 62.70 ng/L in the saline control group, and a substantial 
decrease in the production of TNF-α was found in the PDAPEI/
pDNA group (45.36 ±  17.61  ng/L, p <  0.01). The levels of 11 
in both the PEI 25 kDA/pDNA (103.56 ± 29.82 ng/L) and PEI 
1.8  kDa/pDNA (93.78 ±  30.42  ng/L) groups were significantly 
higher than that in the PDAPEI/pDNA group, but lower than that 
in the saline control group (p < 0.05) (Figure 6A). The western-
blot analysis corresponded with the ELISA results (Figure 6B).
histological examination
Safranin O/fast green staining and anti-TNF-α immunohis-
tochemical analysis were used for to examine the histology. 
As shown in Figure 7A, the histological cross-sections of knee 
joints revealed almost normal safranin O-stained (red) proteo-
glycans in the PDAPEI/pDNA group, with a smooth cartilage 
surface. Almost no proteoglycans were left in the saline control 
group. TNF-α immunohistochemistry staining showed that 
TNF-α was abundant in knee joint tissues taken from the saline 
FigUre 6 | TnF-α expression in synovial fluid of the knees. (a) TNF-α levels in synovial fluid of the knees from four groups (PDAPEI/pDNA, PEI 25 kDa/pDNA, 
PEI 1.8 kDa/pDNA, and saline control group) were determined by enzyme-linked immunosorbent assay (ELISA). Values are the mean and SEM from six different 
mice. (B) Western-blot analysis of TNF-α levels in synovial fluid of the knees (n = 6 in each group, *p < 0.05, **p < 0.01).
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control group. However, the signal for TNF-α staining in the 
PDAPEI/pDNA group was hardly visible, revealing a marked 
inhibition of TNF-α protein levels (Figure 7B).
DiscUssiOn
The aim of this study was to develop an efficient and non-toxic 
delivery system for TNF-α shRNA in RA. RNA interference 
is the ability to exogenously introduce double-stranded RNA 
(dsRNA) molecules to inhibit the expression of specific gene 
homologs (13,  28). It has been utilized to effectively treat a 
variety of diseases, such as viral infections, cancer, and autoim-
mune disorders, by blocking gene expression in its target cells 
(29, 30). An optimal vector is needed to deliver the gene with 
high transfection efficiency and low cytotoxicity. In this study, 
PDAPEI condensed pDNA completely at a w/w ratio of 2, formed 
a homogeneous sphere with a particle size of 80 nm with a stable 
positive zeta potential of 22 mV. Particle size and zeta potential 
demonstrate the ability of DNA binding and affect cellular endo-
cytosis and gene transfection efficiency (31). These characters 
made PDAPEI a perfect vector for gene transfer. We found a cell 
viability score of more than 90% and had higher transfection 
efficiency than with the PEI 25 kDa positive control. Different 
cationic polymers as gene carriers for Raw 264.7 cell have been 
investigated. Mannosylated chitosan-graft-PEI and degradable 
cationic monomers have shown great transfection ability, and 
the transfection efficiency is more than 40%, while the cell 
viability after transfection is lower than 80% (32–34). PDAPEI 
has the advantages of being non-toxic and possessing efficient 
transfection efficiency. One possible explanation is PDAPEI can 
metabolize itself into non-toxic PEI 1.8 kDa and 2,6-PDA under 
acidic environment conditions.
TNF-α plays a central role in the development and progres-
sion of RA and the main gene target for treatment (35). In our 
in  vitro study, TNF-α shRNA was successfully transfected 
into macrophages and its expression level was significantly 
decreased. PDAPEI/pDNA had significantly better TNF-α 
inhibition results than the other three groups because of its high 
transfection efficiency and low cytotoxicity. TNF-α participates 
in cartilage/bone degradation and promotes other the secretion 
of other cytokines (36). Upon histological examination, anti-
TNF-α immunohistochemical analysis indicated that PDAPEI/
pDNA suppressed the expression of TNF-α. Furthermore, the 
PDAPEI/pDNA group yielded a better clinical examination 
FigUre 7 | continued
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result. These results demonstrate that PDAPEI/pDNA decreased 
the severity of arthritis in mice with CIA by inhibiting TNF-α 
expression.
Rheumatoid arthritis is a systemic autoimmune disease, char-
acterized by non-organ-specific autoantibody production and 
chronic inflammation of the synovial tissues, leading to cartilage 
and bone destruction (37). Treatments, such as anti-TNF-α 
monoclonal antibodies, have been successfully developed but 
had limited application due to complications (38, 39). However, 
TNF-α shRNA is a powerful tool to specifically silence gene 
expression, and the repair results further proved its outcome in 
our experiment.
FigUre 7 | histological examination. (a) Safranin O/fast green staining (red: cartilage, gray green: cytoplasm). (B) anti-TNF-α staining (brown: TNF-α) of 4 
experimental group (PDAPEI/pDNA, PEI 25 kDa/pDNA, PEI 1.8 kDa/pDNA and saline control group) and normal knee joint. Scale bar = 100 μm.
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